Medivation, Inc. Investor Files Lawsuit Over Alleged Securities Laws Violations

If you purchased Medivation, Inc. (NASDAQ:MDVN) common stock between July 17, 2008 and March 2, 2010, you have certain options and there are strict and short deadlines running. Deadline: May 10, 2010. Those MDVN investors and current long term MDVN shareholders should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Medivation
Case Name: 
Medivation Shareholder Class Action 03/09/2010
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: MDVN
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
03/09/2010
Class Period Begin: 
07/17/2008
Class Period End: 
03/02/2010
Court of Filing: 
U.S. District Court for the Northern District of California
Deadline To File for Lead: 
05/10/2010
Summary: 

An investors with Medivation, Inc. (NASDAQ:MDVN) filed a lawsuit in the United States District Court for the Northern District of California on behalf of purchasers of Medivation, Inc. (NASDAQ:MDVN) common stock during the period between July 17, 2008 and March 2, 2010, against Medivation.

Medivation, Inc., located in San Francisco, California, is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer’s disease, Huntington’s disease and castration-resistant prostate cancer. According to the complaint, the plaintiff alleges that Medivation, Inc. and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing between July 17, 2008 and March 2, 2010 false and misleading statements regarding its drug Dimebon. Then, on March 3, 2010, before the market opened, defendants were forced to publicly disclose that Dimebon did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer’s disease, and as a result of this news, Medivation’s stock plummeted $27.15 per share to close at $13.10 per share on March 3, 2010 – a one-day decline of 67%, so the lawsuit. Shares of Medivation, Inc. (NASDAQ:MDVN) continued to decline from its 52weekHigh of $40.49 per share to $12.10 per share on Tuesday, March 09, 2010.